Cargando…
The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia
Benign prostatic hyperplasia (BPH) is characterized by an enlarged prostate, lower urinary tract symptoms (LUTS), and a decreased urinary flow rate. Common in older men, BPH is a progressive disease that can eventually lead to complications including acute urinary retention (AUR) and the need for BP...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Second Military Medical University
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5780290/ https://www.ncbi.nlm.nih.gov/pubmed/29379733 http://dx.doi.org/10.1016/j.ajur.2017.11.005 |
_version_ | 1783294705444847616 |
---|---|
author | Kim, Eric H. Brockman, John A. Andriole, Gerald L. |
author_facet | Kim, Eric H. Brockman, John A. Andriole, Gerald L. |
author_sort | Kim, Eric H. |
collection | PubMed |
description | Benign prostatic hyperplasia (BPH) is characterized by an enlarged prostate, lower urinary tract symptoms (LUTS), and a decreased urinary flow rate. Common in older men, BPH is a progressive disease that can eventually lead to complications including acute urinary retention (AUR) and the need for BPH-related surgery. Both normal and abnormal prostate growth is driven by the androgen dihydrotestosterone (DHT), which is formed from testosterone under the influence of 5-alpha reductase. Thus, 5-alpha reductase inhibitors (5-ARIs) effectively reduce the serum and intraprostatic concentration of DHT, causing an involution of prostate tissue. Two 5-ARIs are currently available for the treatment of BPH—finasteride and dutasteride. Both have been demonstrated to decrease prostate volume, improve LUTS and urinary flow rates, which ultimately reduces the risk of AUR and BPH-related surgery. Therefore, either alone or in combination with other BPH medications, 5-ARIs are a mainstay of BPH management. |
format | Online Article Text |
id | pubmed-5780290 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Second Military Medical University |
record_format | MEDLINE/PubMed |
spelling | pubmed-57802902018-01-29 The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia Kim, Eric H. Brockman, John A. Andriole, Gerald L. Asian J Urol Review Benign prostatic hyperplasia (BPH) is characterized by an enlarged prostate, lower urinary tract symptoms (LUTS), and a decreased urinary flow rate. Common in older men, BPH is a progressive disease that can eventually lead to complications including acute urinary retention (AUR) and the need for BPH-related surgery. Both normal and abnormal prostate growth is driven by the androgen dihydrotestosterone (DHT), which is formed from testosterone under the influence of 5-alpha reductase. Thus, 5-alpha reductase inhibitors (5-ARIs) effectively reduce the serum and intraprostatic concentration of DHT, causing an involution of prostate tissue. Two 5-ARIs are currently available for the treatment of BPH—finasteride and dutasteride. Both have been demonstrated to decrease prostate volume, improve LUTS and urinary flow rates, which ultimately reduces the risk of AUR and BPH-related surgery. Therefore, either alone or in combination with other BPH medications, 5-ARIs are a mainstay of BPH management. Second Military Medical University 2018-01 2017-11-26 /pmc/articles/PMC5780290/ /pubmed/29379733 http://dx.doi.org/10.1016/j.ajur.2017.11.005 Text en © 2018 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Review Kim, Eric H. Brockman, John A. Andriole, Gerald L. The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia |
title | The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia |
title_full | The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia |
title_fullStr | The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia |
title_full_unstemmed | The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia |
title_short | The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia |
title_sort | use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5780290/ https://www.ncbi.nlm.nih.gov/pubmed/29379733 http://dx.doi.org/10.1016/j.ajur.2017.11.005 |
work_keys_str_mv | AT kimerich theuseof5alphareductaseinhibitorsinthetreatmentofbenignprostatichyperplasia AT brockmanjohna theuseof5alphareductaseinhibitorsinthetreatmentofbenignprostatichyperplasia AT andriolegeraldl theuseof5alphareductaseinhibitorsinthetreatmentofbenignprostatichyperplasia AT kimerich useof5alphareductaseinhibitorsinthetreatmentofbenignprostatichyperplasia AT brockmanjohna useof5alphareductaseinhibitorsinthetreatmentofbenignprostatichyperplasia AT andriolegeraldl useof5alphareductaseinhibitorsinthetreatmentofbenignprostatichyperplasia |